Amorcyte

Amorcyte secures production capacity for lead cell therapy product

Published in Medical Verdicts and Law Weekly, July 27th, 2006

Amorcyte, Inc., a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, has signed an exclusive agreement for the development and manufacturing of Amorcyte's lead product, AMR-001, with Progenitor Cell Therapy, LLC (PCT), a full service cell therapy development and contract manufacturing company.

"The product development and manufacturing agreement with Progenitor Cell Therapy is a critical component of our corporate and product development plan," explained Thomas Moss, Amorcyte's chief medical officer. "Our strategic relationship with PCT enables our development team to draw on PCT's unique and extensive investigative,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly

Source: Medical Verdicts and Law Weekly (2006-07-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry